Surgical Oncology Principles — MCQs

Surgical Oncology Principles Indian Medical PG Practice Questions and MCQs

Question 51: Which of the following is NOT considered a poor prognostic factor in liver metastasis?

A. Synchronous lesions
B. Metachronous lesions (Correct Answer)
C. Extra-hepatic metastasis
D. CEA > 200 ng/ml

Explanation: **Explanation:** The prognosis of liver metastasis, particularly from colorectal cancer, is determined by the **Fong Criteria (Clinical Risk Score)**. This scoring system helps predict recurrence and survival after surgical resection. **1. Why Metachronous lesions is the correct answer:** Metachronous lesions (metastases appearing >12 months after the primary tumor) are considered a **favorable prognostic factor** compared to synchronous lesions. A longer disease-free interval indicates a less aggressive tumor biology and a slower rate of spread, leading to better post-resection outcomes. **2. Analysis of Incorrect Options (Poor Prognostic Factors):** * **Synchronous lesions (Option A):** These are metastases detected at the same time as or within 12 months of the primary tumor. They indicate aggressive biology and are associated with a higher risk of recurrence. * **Extra-hepatic metastasis (Option B):** The presence of disease outside the liver (e.g., lung or peritoneal spread) signifies systemic involvement, significantly worsening the prognosis and often contraindicating curative resection. * **CEA > 200 ng/ml (Option D):** High preoperative Carcinoembryonic Antigen (CEA) levels are a strong biochemical marker for high tumor burden and poor survival outcomes. **Clinical Pearls for NEET-PG:** * **Fong’s Clinical Risk Score (CRS)** includes 5 factors: Node-positive primary, Disease-free interval <12 months, Number of tumors >1, Largest tumor >5 cm, and CEA >200 ng/ml. * **Resectability** is no longer defined by what is removed, but by what is left behind (the **Future Liver Remnant - FLR**). A minimum of 20-25% of healthy liver parenchyma is required. * The most common site of distant metastasis for colorectal cancer is the **liver** (via portal circulation).

Question 52: What is the ideal treatment for a 3.4 cm carcinoid tumor of the appendix?

A. Right hemicolectomy (Correct Answer)
B. Radiotherapy
C. Chemotherapy
D. Observation

Explanation: **Explanation:** The management of appendiceal carcinoid tumors (neuroendocrine tumors) is primarily determined by the **size of the tumor** and its location. 1. **Why Right Hemicolectomy is correct:** For appendiceal carcinoids, an appendectomy is sufficient if the tumor is <1 cm. However, a **Right Hemicolectomy** is indicated if the tumor is **>2 cm** (as in this case, 3.4 cm), because the risk of nodal metastasis increases significantly with size. Other indications for right hemicolectomy regardless of size include involvement of the base of the appendix, mesoappendiceal invasion, or high-grade histology (Goblet cell carcinoid). 2. **Why other options are incorrect:** * **Radiotherapy & Chemotherapy:** Carcinoid tumors are generally slow-growing (indolent) and are notoriously resistant to conventional radiotherapy and chemotherapy. Surgery remains the mainstay of treatment for localized disease. * **Observation:** This is inappropriate for a 3.4 cm mass due to the high risk of malignancy and lymphatic spread. Observation is only considered for very small, incidentally found tumors post-appendectomy that meet all low-risk criteria. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site** of carcinoid tumors in the GI tract: **Ileum** (though historically often cited as Appendix in older texts; current data suggests Small Bowel > Rectum > Appendix). * **Most common site within the appendix:** The **tip** (distal third). * **Carcinoid Syndrome:** Usually occurs only when there are **liver metastases** (bypassing portal circulation). * **Tumor Marker:** **Chromogranin A** (most sensitive) and 24-hour urinary **5-HIAA**. * **Diagnostic Rule of Thumb:** * <1 cm: Appendectomy. * 1–2 cm: Appendectomy (unless at the base or high-risk features). * >2 cm: Right Hemicolectomy.

Question 53: Which of the following is true about bronchial carcinoids?

A. Highly radiosensitive
B. Metastasis is common (Correct Answer)
C. Carcinoid syndrome does not manifest
D. Commonly arise from terminal bronchioles

Explanation: **Explanation:** Bronchial carcinoids are neuroendocrine tumors arising from **Kulchitsky cells** of the bronchial epithelium. While often classified as "low-grade" compared to small cell carcinoma, they are nonetheless malignant. **Why Option B is Correct:** Contrary to the misconception that they are benign, bronchial carcinoids are inherently malignant. **Metastasis is common**, occurring in approximately **15–20% of typical carcinoids** and up to **50–70% of atypical carcinoids**. Metastasis usually involves the regional (hilar and mediastinal) lymph nodes, followed by distant sites like the liver and bone. **Analysis of Incorrect Options:** * **Option A:** Bronchial carcinoids are generally **radioresistant**. The primary treatment of choice is surgical resection (e.g., lobectomy or sleeve resection). * **Option C:** While rare (occurring in <5% of cases), **carcinoid syndrome can manifest**, especially when there are extensive liver metastases. Interestingly, bronchial carcinoids can sometimes cause the syndrome even without liver metastasis because their secretions enter the systemic circulation directly via the pulmonary veins, bypassing the portal circulation. * **Option D:** Most bronchial carcinoids (approx. 80%) are **central**, arising from the **large (mainstem/lobar) bronchi**, not the terminal bronchioles. This central location often leads to symptoms like persistent cough, hemoptysis, and obstructive pneumonia. **High-Yield NEET-PG Pearls:** * **Histology:** Look for a "salt and pepper" chromatin pattern and organoid growth. * **Classification:** Divided into **Typical** (<2 mitoses/10 HPF, no necrosis) and **Atypical** (2–10 mitoses/10 HPF or necrosis). * **Markers:** Positive for Chromogranin A, Synaptophysin, and CD56. * **Paraneoplastic Syndromes:** Bronchial carcinoids are a known cause of ectopic **ACTH production**, leading to Cushing’s syndrome.

Question 54: A 60-year-old lady presents with a 4 cm breast mass and ipsilateral infraclavicular lymphadenopathy. What is the clinical stage of the breast cancer?

A. T2N2
B. T2N3 (Correct Answer)
C. T3N2
D. T3N3

Explanation: ### **Explanation** This question tests your knowledge of the **AJCC TNM Staging (8th Edition)** for breast cancer, which is a high-yield topic for NEET-PG. **1. Why T2N3 is Correct:** * **T (Tumor Size):** The mass is **4 cm**. According to TNM staging, T2 is defined as a tumor >2 cm but ≤5 cm in its greatest dimension. * **N (Nodal Status):** The patient has **ipsilateral infraclavicular lymphadenopathy**. In the AJCC classification, involvement of the infraclavicular (Level III) nodes is specifically categorized as **N3a**. * Combining these, the clinical stage is **T2N3**. **2. Why Other Options are Incorrect:** * **T2N2:** While the T-stage is correct, N2 refers to fixed/matted axillary nodes (N2a) or clinically detected internal mammary nodes in the absence of axillary nodes (N2b). It does not include infraclavicular nodes. * **T3N2 & T3N3:** T3 is defined as a tumor **>5 cm**. Since this mass is 4 cm, these options are incorrect. **3. Clinical Pearls for NEET-PG:** * **Nodal Staging Cheat Sheet:** * **N1:** Mobile ipsilateral axillary nodes (Level I, II). * **N2:** Fixed/matted ipsilateral axillary nodes OR internal mammary nodes. * **N3:** Infraclavicular (N3a), Internal mammary + Axillary (N3b), or Supraclavicular (N3c) nodes. * **Stage III Distinction:** Any N3 involvement automatically places the patient in **Stage IIIC**, regardless of the T stage (unless T4, which is also Stage IIIB/C). * **Remember:** Infraclavicular nodes are Level III axillary nodes, but for staging purposes, they are classified as N3.

Question 55: Carcinoma of the lip is characterized by the following except:

A. 90% of lip cancers occur on the lower lip.
B. The most common site of origin is the vermillion border.
C. 2 cm x 2 cm cell carcinomas can be treated by V-shaped excision and primary closure.
D. Lymph node metastases are common, making radical neck dissection mandatory. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is the correct (incorrect statement):** While lip cancer can spread to regional lymph nodes (submental and submandibular), the incidence of clinically positive nodes at presentation is relatively low (approx. 5–10%). Therefore, **prophylactic or radical neck dissection is NOT mandatory** for all cases. Management of the neck is typically "watchful waiting" for early lesions (T1-T2) or selective neck dissection only if nodes are clinically palpable or the primary tumor is high-risk/advanced. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** Approximately **90% of lip cancers occur on the lower lip**, primarily due to cumulative solar radiation exposure. Upper lip cancers are rarer but often more aggressive. * **Option B:** The **vermillion border** (the transition zone between the skin and mucous membrane) is the most common site of origin, specifically for Squamous Cell Carcinoma (SCC). * **Option C:** Small to medium-sized lesions (up to 1/3rd of the lip width, roughly 2 cm) can be effectively managed by a **V-shaped or Shield excision** with primary closure. The lip's inherent laxity allows for excellent functional and cosmetic results with this technique. **Clinical Pearls for NEET-PG:** * **Most common histology:** Squamous Cell Carcinoma (SCC) is most common on the lower lip; Basal Cell Carcinoma (BCC) is more frequent on the upper lip. * **Risk Factors:** Chronic sun exposure (UVB), pipe smoking, and immunosuppression. * **Prognosis:** Lip cancer generally has a better prognosis than other oral cavity cancers because it is detected early and has a lower rate of nodal metastasis. * **Reconstruction Rule:** If a defect is >1/3 but <2/3 of the lip, local flaps like the **Abbe-Estlander flap** or **Karapandzic flap** are used.

Question 56: Postoperative radiotherapy in breast cancer is indicated for which of the following reasons?

A. Prevention of metastasis
B. Ablation of remnant cancer tissue
C. Prevention of local recurrence (Correct Answer)
D. Prevention of distant metastasis

Explanation: **Explanation:** The primary objective of postoperative (adjuvant) radiotherapy in breast cancer management is the **prevention of local and regional recurrence**. **1. Why the correct answer is right:** Radiotherapy works by delivering ionizing radiation to the chest wall and/or regional lymph nodes to eradicate microscopic residual disease that may remain after surgery (either Breast Conserving Surgery or Mastectomy). While surgery addresses the macroscopic tumor, radiotherapy targets the surgical bed to ensure local control. Large clinical trials (e.g., EBCTCG meta-analysis) have consistently shown that adjuvant RT significantly reduces the risk of local recurrence by approximately two-thirds. **2. Why the incorrect options are wrong:** * **Options A & D (Prevention of metastasis/distant metastasis):** Radiotherapy is a **locoregional treatment**. It does not directly prevent distant metastasis. Distant spread is managed via systemic therapies (Chemotherapy, Hormonal therapy, or Targeted therapy). While better local control can indirectly lead to a slight improvement in long-term breast cancer-specific survival, its primary indication is not the prevention of distant spread. * **Option B (Ablation of remnant cancer tissue):** "Ablation" usually refers to the intentional destruction of a known, visible tissue mass (like radiofrequency ablation). Postoperative RT is "adjuvant," meaning it targets *suspected* microscopic cells, not gross remnant tissue. If gross tumor is left behind, it is considered an incomplete resection (R1/R2), which requires re-excision rather than just RT. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Indication:** RT is mandatory for **all** patients undergoing Breast Conserving Surgery (BCS). * **Post-Mastectomy RT (PMRT) Indications:** Tumor size **>5 cm (T3)**, positive surgical margins, or **≥4 positive axillary lymph nodes** (N2). * **Standard Dose:** Usually 40-50 Gy delivered in fractionated doses. * **Side Effects:** Acute (radiation dermatitis) and Late (breast fibrosis, lymphedema, and rare risks like pneumonitis or secondary angiosarcoma).

Question 57: Which of the following represents a curative resection?

A. R0 (Correct Answer)
B. R1
C. R2
D. R3

Explanation: ### Explanation The classification of surgical resection margins is based on the **Residual Tumor (R) Classification** system, which describes the status of the tumor remaining after a surgical procedure. **1. Why R0 is the Correct Answer:** An **R0 resection** indicates a **complete macroscopic and microscopic removal** of the tumor. There are no tumor cells at the resection margins when examined by a pathologist (negative margins). In surgical oncology, R0 is the gold standard and the only category that represents a **curative resection**, as it implies that all local disease has been eradicated. **2. Why the Other Options are Incorrect:** * **R1 Resection:** This refers to **microscopic residual tumor**. While the surgeon may believe they removed the entire mass (macroscopically clear), the pathologist finds tumor cells at the margin under the microscope. This is considered an incomplete resection. * **R2 Resection:** This refers to **macroscopic residual tumor**. The surgeon is aware that visible tumor was left behind (e.g., tumor debulking or involvement of unresectable vital structures). This is a palliative, not curative, procedure. * **R3:** This is not a standard part of the AJCC/UICC R-classification system. The scale traditionally ends at R2. **Clinical Pearls for NEET-PG:** * **The 1 cm Rule:** Traditionally, a 1 cm clear margin was sought for many solid tumors (like colorectal cancer), though modern "negative margin" definitions vary by organ (e.g., "no ink on tumor" for breast conservation). * **CRM (Circumferential Resection Margin):** Crucial in rectal cancer; a CRM of <1 mm is considered an R1 resection and predicts high local recurrence. * **Palliative Surgery:** R2 resections are often performed to relieve symptoms like obstruction or bleeding, even when cure is impossible.

Question 58: Adjuvant chemotherapy is of definite value in which of the following conditions?

A. Colon cancer (Correct Answer)
B. Pancreatic cancer
C. Gall bladder cancer
D. Esophageal cancer

Explanation: **Explanation:** **Adjuvant chemotherapy** refers to the administration of systemic agents after definitive local treatment (surgery) to eliminate micrometastases and reduce the risk of recurrence. 1. **Why Colon Cancer is Correct:** In **Stage III colon cancer** (node-positive), adjuvant chemotherapy (typically FOLFOX or CAPOX) is the **standard of care** and has been definitively proven to improve overall survival and disease-free survival. For Stage II patients with high-risk features (e.g., T4 tumors, lymphovascular invasion), it also provides a clear benefit. It is one of the most successful applications of adjuvant therapy in solid organ malignancies. 2. **Why Other Options are Incorrect:** * **Pancreatic Cancer:** While adjuvant chemotherapy (FOLFIRINOX or Gemcitabine) is used, the prognosis remains poor, and the "definite value" in terms of long-term cure rates is significantly lower than in colon cancer. * **Gallbladder Cancer:** The role of adjuvant chemotherapy is still evolving. While often used in T2+ or node-positive cases (based on the BILCAP trial), the evidence base is less robust compared to the established protocols for colon cancer. * **Esophageal Cancer:** The standard of care for locally advanced esophageal cancer is typically **neoadjuvant** (pre-operative) chemoradiotherapy (CROSS protocol). Adjuvant therapy is generally reserved only for specific cases with residual disease. **High-Yield Clinical Pearls for NEET-PG:** * **Neoadjuvant Therapy:** Preferred in Rectal cancer (to downstage and preserve the sphincter) and Esophageal cancer. * **Adjuvant Therapy:** Definitive gold standard for Stage III Colon cancer and Breast cancer. * **CEA (Carcinoembryonic Antigen):** The most important tumor marker for monitoring recurrence in colon cancer post-adjuvant therapy. * **Microsatellite Instability (MSI):** High MSI (MSI-H) Stage II colon cancer patients actually have a good prognosis and may not benefit from 5-FU monotherapy.

Question 59: The proper treatment for lobular carcinoma in situ (LCIS) includes which of the following components?

A. Close follow-up. (Correct Answer)
B. Radiation after excision.
C. Mirror-image biopsy of the opposite breast.
D. Mastectomy and regional node dissection.

Explanation: **Explanation:** Lobular Carcinoma In Situ (LCIS) is fundamentally different from Ductal Carcinoma In Situ (DCIS). While DCIS is a precursor lesion, **LCIS is primarily considered a risk factor (indicator)** for the future development of invasive breast cancer in *either* breast. **1. Why "Close follow-up" is correct:** Since LCIS is a marker of increased risk (approximately 7-10 times higher than the general population) rather than a direct pre-malignant lesion, the standard management is **observation/surveillance**. This includes regular clinical breast exams and annual mammography. In high-risk patients, chemoprevention with Selective Estrogen Receptor Modulators (SERMs) like Tamoxifen or Raloxifene may be added to reduce the risk of future invasive cancer. **2. Why other options are incorrect:** * **B. Radiation after excision:** Unlike DCIS, LCIS is often multicentric and bilateral. Radiation to a single site does not address the global risk to both breasts and is not indicated. * **C. Mirror-image biopsy:** While LCIS is frequently bilateral, routine "blind" biopsy of the opposite breast is no longer recommended. Modern imaging (MRI/Mammography) is used for surveillance instead. * **D. Mastectomy and regional node dissection:** LCIS does not metastasize to lymph nodes. Bilateral prophylactic mastectomy is only considered in very high-risk cases (e.g., BRCA mutations or strong family history) but is never the routine "proper treatment." **Clinical Pearls for NEET-PG:** * **Incidental Finding:** LCIS is usually an incidental finding on biopsy; it has no specific mammographic or clinical features (no mass/calcifications). * **Bilateral Risk:** The risk of developing invasive cancer is equal for both the ipsilateral and contralateral breast. * **Pleomorphic LCIS:** A rare subtype that behaves more aggressively like DCIS; this specific variant *does* require surgical excision with clear margins. * **Most common invasive cancer after LCIS:** Despite its name, the most common invasive cancer that develops after LCIS is actually **Invasive Ductal Carcinoma**.

Question 60: Which of the following is NOT a surrogate marker for assessing a patient's physical reserve to plan oncological treatment?

A. Karnofsky performance status
B. ECOG performance score
C. Child-Pugh score
D. MSKCC neutropenia risk score (Correct Answer)

Explanation: **Explanation:** In oncological surgery and chemotherapy planning, assessing a patient’s **physical reserve** (Performance Status) is critical to determine if they can tolerate aggressive treatment. **Why MSKCC Neutropenia Risk Score is the correct answer:** The MSKCC (Memorial Sloan Kettering Cancer Center) neutropenia risk score is a **predictive tool** used specifically to estimate the likelihood of a patient developing febrile neutropenia following chemotherapy. It focuses on hematological toxicity rather than the patient's overall functional capacity or baseline physical reserve. Therefore, it is not a surrogate marker for general performance status. **Analysis of Incorrect Options:** * **Karnofsky Performance Status (KPS):** A classic scale ranging from 0 to 100. It measures a patient's ability to perform daily activities and need for medical assistance. A higher score indicates better physical reserve. * **ECOG Performance Score:** Developed by the Eastern Cooperative Oncology Group, this scales from 0 (fully active) to 5 (dead). It is the most widely used tool in clinical trials to decide if a patient is fit for surgery or chemotherapy. * **Child-Pugh Score:** While primarily used for cirrhosis, in the context of **Hepatocellular Carcinoma (HCC)**, it is a vital surrogate marker for hepatic physical reserve. It dictates whether a patient can undergo major liver resection (usually reserved for Child-Pugh Class A). **High-Yield Clinical Pearls for NEET-PG:** * **ECOG 0-1:** Generally fit for aggressive surgery/chemotherapy. * **ECOG ≥3:** Usually candidates for palliative care rather than curative surgical resection. * **KPS <70%:** Indicates the patient is unable to care for themselves; prognosis is generally poor. * **Child-Pugh Components:** Remember the mnemonic **ABCDE** (Albumin, Bilirubin, Coagulation/INR, Distension/Ascites, Encephalopathy).

Practice by Chapter

Cancer Biology Basics

Practice Questions

Principles of Cancer Therapy

Practice Questions

Screening and Early Detection

Practice Questions

Surgical Staging

Practice Questions

Surgical Resection Principles

Practice Questions

Lymphadenectomy

Practice Questions

Management of Metastatic Disease

Practice Questions

Combined Modality Therapy

Practice Questions

Targeted Therapy Concepts

Practice Questions

Cancer Survivorship

Practice Questions

Palliative Surgical Interventions

Practice Questions

Ethics in Cancer Care

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free